wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q36270115-FD3CB192-1FBE-4010-B531-8ED9D1BE257A
Q36270115-FD3CB192-1FBE-4010-B531-8ED9D1BE257A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36270115-FD3CB192-1FBE-4010-B531-8ED9D1BE257A
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
P2860
Q36270115-FD3CB192-1FBE-4010-B531-8ED9D1BE257A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36270115-FD3CB192-1FBE-4010-B531-8ED9D1BE257A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
015154f7559a0a7e6ab1c36a57dc78dfad175e13
P2860
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.